Pneumococcal Polysaccharide Conjugate Vaccine

Abstract

The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent Streptococcus pneumoniae immunogenic composition is provided with various conjugated capsular saccharides from different S. pneumoniae serotypes conjugated to 2 or more different carrier proteins, where the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT) or CRM197, optionally wherein 19F is the only saccharide in the composition conjugated to diphtheria toxoid (DT) or CRM197.

1 . A  Streptococcus pneumoniae  immunogenic composition comprising 9 or more capsular saccharides from different  S. pneumoniae  serotypes conjugated to 2 or more different carrier proteins, wherein the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT) or CRM197. 
     
     
         2 . An immunogenic composition according to  claim 1  wherein serotype 19F is conjugated to Diphtheria toxoid. 
     
     
         3 . (canceled) 
     
     
         4 . An immunogenic composition according to  claim 1  wherein 19F capsular saccharide is directly conjugated to the carrier protein. 
     
     
         5 . An immunogenic composition according to  claim 1  wherein 19F capsular saccharide is conjugated to the carrier protein via a linker. 
     
     
         6 - 10 . (canceled) 
     
     
         11 . The immunogenic composition of  claim 1  wherein the 19F saccharide is conjugated to the carrier protein or to the linker using CDAP chemistry. 
     
     
         12 . The immunogenic composition of  claim 1  wherein the ratio of carrier protein to 19F saccharide is between 5:1 and 1:5 (w/w). 
     
     
         13 . The immunogenic composition of  claim 1  wherein the average size of the 19F saccharide is above 100 kDa. 
     
     
         14 - 16 . (canceled) 
     
     
         17 . The immunogenic composition of  claim 1  wherein the dose of the 19F saccharide conjugate is between 1 and 10 μg of saccharide. 
     
     
         18 - 19 . (canceled) 
     
     
         20 . An immunogenic composition according to  claim 1  comprising 2 different carrier proteins. 
     
     
         21 . (canceled) 
     
     
         22 . An immunogenic composition according to  claim 1  wherein one or more or all carrier proteins is selected from the group consisting of DT, CRM 197, TT, Fragment C, dPly, PhtA, PhyB, PhtD, PhtE, PhtDE, OmpC, PorB and  Haemophilus influenzae  Protein D. 
     
     
         23 - 26 . (canceled) 
     
     
         27 . An immunogenic composition according to  claim 1  wherein the composition comprises capsular saccharide 18C conjugated to TT. 
     
     
         28 - 116 . (canceled) 
     
     
         117 . A method of immunising a human host against disease caused by  Streptococcus pneumoniae  infection comprising administering to the host an immunoprotective dose of the immunogenic composition of  claim 1 . 
     
     
         118 - 130 . (canceled) 
     
     
         131 . A method of immunising a human host against disease caused by  Streptococcus pneumoniae  serotype 19A infection comprising the steps of administering to the host an immunoprotective dose of the immunogenic composition of  claim 1  which comprises a capsular saccharide conjugate of serotype 19F but does not comprise capsular saccharide from serotype 19A. 
     
     
         132 - 150 . (canceled) 
     
     
         151 . The immunogenic composition of  claim 1  comprising serotype 19F capsular saccharide but not comprising capsular sacccharide from serotype 19A. 
     
     
         152 . A  Streptococcus pneumoniae  immunogenic composition comprising 9 or more capsular saccharides from different  S. pneumoniae  serotypes conjugated to 2 or more different carrier proteins, wherein the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT) or CRM197, wherein 19F is the only saccharide in the composition conjugated to diphtheria toxoid (DT) or CRM197. 
     
     
         153 . An immunogenic composition according to  claim 20  wherein one or more or all carrier proteins is selected from the group consisting of DT, CRM 197, TT, Fragment C, dPly, PhtA, PhyB, PhtD, PhtE, PhtDE, OmpC, PorB and  Haemophilus influenzae  Protein D. 
     
     
         154 . An immunogenic composition according to  claim 1  wherein the composition comprises capsular saccharide 18C conjugated to TT, wherein 18C is the only saccharide in the composition conjugated to tetanus toxoid (TT).